Target ALS

Meet Ann Hu, one of our dedicated runners on #TeamTargetALS for the TCS New York City Marathon! After graduating, Ann became a Clinical Research Coordinator at the Massachusetts General Hospital Center for ALS Research, where she had the privilege of overseeing the care of many ALS patients. Although she has since moved on from that role, ALS advocacy remains close to her heart. As she embarks on her journey as a physician, Ann is determined to make a tangible impact on ALS research and patient care. “With Target ALS, I hope to raise awareness and funds that will push us closer to better treatments, turning strides into significant steps forward,” says Ann. Join Ann in her mission to raise funds for ALS Research, to create a world where Everyone Lives. Every donation counts: https://bit.ly/4cYtqah #ALSResearch #NYCMarathon #EveryoneLives #DonateNow

We are thrilled to announce that the Caribbean Hispanic Amyotrophic Lateral Sclerosis Center for Clinical Trials (CHALS-CCT) at the University of Puerto Rico has successfully enrolled its first patient in the Target ALS Global Natural History Study. The study aims to create the most comprehensive collection of biofluids - including blood, urine, and cerebrospinal fluid - and data from people with ALS and healthy control participants to help scientists advance ALS research. By expanding our study globally and including diverse and underrepresented populations in clinical research, we can improve our understanding of ALS and accelerate the discovery of treatments that will help all people living with this disease. Learn more about the study and view our active sites: https://bit.ly/3z8y3kd #EveryoneLives #ALSResearch #GlobalStudy #RadicalCollaboration

We are excited to welcome Christine Aranyos Prouty as our new Director of Philanthropy at Target ALS! With a passion for advancing meaningful missions and a strong commitment to collaborative innovation, Christine brings a wealth of experience in driving meaningful partnerships that will accelerate the path to new treatments. We look forward to the significant contributions Christine will make as we continue to break down barriers to ALS research and work towards a future where #EveryoneLives. #TargetALS #ALSResearch #TeamUpdate

Our founder, Dan Doctoroff, was a driving force behind bringing the half marathon to NYC during his time as Deputy Mayor. Now, as he courageously faces ALS himself, we’re proud to carry forward his legacy by raising awareness and funds for ALS research with Team Target ALS. We are thrilled to announce that Target ALS is an official charity partner of the TCS New York City Marathon on November 3, 2024! Our team of nine incredible runners will take on the challenge of 26.2 miles, each with a goal of raising $3,000 to support groundbreaking ALS research. Join us in supporting our runners and our vision to create a world where Everyone Lives. Every donation counts! Support our runners here: https://bit.ly/3APmr62 Video Credits: New York's WPIX-TV (Channel 11) www.pix11.com #ALSResearch #NYCMarathon #EveryoneLives

We're #hiring a new Data Scientist in the United States. Apply today or share this post with your network!

The Target ALS Data Engine just got bigger. We've expanded datasets across all core collections, including new whole genome sequencing, RNA sequencing, spatial transcriptomics data, longitudinal speech data, stem cell lines, and more. To enhance your experience, we've also introduced a comprehensive user manual and new demo videos for each collection. These additions are designed to help researchers navigate the platform with ease and fully utilize the rich datasets available. By providing these new tools, we aim to empower scientists to accelerate ALS research, drive breakthroughs in biomarker discovery, and advance the development of effective therapies. Read more: https://bit.ly/47bo1eN Explore the latest updates and take your research further: https://bit.ly/4cTg6nD #ALSResearch #DataEngine #TargetALS #ResearchImpact #EveryoneLives

Milestone Achieved: Target Identification Two Target ALS funded consortia have identified a promising potential diagnostic biomarker, HDGFL2 cryptic peptide, which appears in the absence of functional TDP-43, an RNA-binding protein whose dysfunction is implicated in 97% of ALS cases. This discovery, supported by leading researchers and industry partners, could revolutionize early diagnosis and therapeutic intervention, potentially improving quality of life and extending lifespan for those living with ALS. At Target ALS, we are proud to accelerate these groundbreaking advancements as we work towards our vision: Everyone Lives. Read more on this milestone and view published work: https://bit.ly/4dNDN1N #ALSResearch #Biomarker #TargetALS #Breakthroughs #RadicalCollaboration

Scientists in the Target ALS innovation ecosystem are exploring the involvement of T cells in ALS, a concept gaining traction due to breakthroughs in cancer treatment. These scientists aim to understand how the balance of T cell types and proteins expressed by T cells impact disease progression, potentially paving the way for new therapeutic interventions. Dr. Jenna Gregory is exploring the involvement of T cells in ALS, focusing on the reactivation of exhausted T cells as a promising therapeutic strategy. These studies aim to understand how restoring the function of exhausted T cells can modulate immune responses, potentially slowing or halting ALS progression. To read more on the Immune System and how it affects ALS: https://bit.ly/3AUBLhG #TargetALS #ALSResearch #ImmuneSystem #TCells #InnovativeTherapies

Ten years ago, the Ice Bucket Challenge swept the world, raising unprecedented awareness and funds for ALS research. It's incredible to reflect on our progress since then, but as Dan's commitment to this cause reminds us, our work is far from over. Together, we must keep pushing forward to find effective treatments for ALS. Watch this powerful video of Dan, the Bloomberg LP team, and Mike Bloomberg taking on the ice bucket challenge ?? https://bit.ly/4dRc0xc #IceBucket10 #ALS #IceBucketChallenge #TargetALS

We are thrilled to announce the recipients of the Target ALS In Vivo Target Validation grants for 2024, a pivotal initiative in collaboration with Biospective Inc. This program focuses on advancing our understanding of TDP-43 in ALS mouse models, accelerating the evaluation of potential therapeutics, and bridging the gap from preclinical research to clinical trials. Through rigorous clinical and molecular assessments, these selected projects aim to provide crucial insights into the treatment of ALS, offering hope for innovative and effective therapies. The exceptional work being done by researchers like Nick J Brandon at Neumora Therapeutics, Jesse Lai at Dewpoint Therapeutics, Nikole Zu?iga Quiroz at Mabylon AG, Ovadia Lazari at NRG Therapeutics, and Baris Bingol at Genentech, represents a significant step forward in the fight against ALS. At Target ALS, our mission is to break down barriers to ALS research to find effective treatments, to realize a world where Everyone Lives. Driven by our values of impatient optimism, deliberate disruption, and radical collaboration, we are dedicated to funding cutting edge research and building partnerships that accelerate progress towards effective treatments for all forms of ALS. To read full project summaries and more, visit: https://bit.ly/46Xvv50 #Collaboration #ALS #ALSResearch #Grant #MedicalResearch #Biospective